Drugs / Oral Poliomyelitis Vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01056705 | Jul 2009 → May 2010 | poliomyelitis | Chinese Academy of Medical Sciences | Completed | No outcome recorded |
| Phase 41 trial · 1 met primary | ||||||
| Phase 4 | NCT01475539 | Nov 2011 → May 2013 | poliomyelitis | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00348881 Background | Jun 2006 → Oct 2007 | diphtheria, hepatitis B virus infection, influenza, pertussis +1 | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Oral Poliomyelitis Vaccine | “Sequential Inactivated Poliomyelitis Vaccine Followed by Oral Poliomyelitis Vaccine Versus Oral Poliomyelitis Vaccine” NCT01475539 ↗ |
| Known as | OPV | “commercially available Oral Poliovirus Vaccine (OPV)” NCT01475539 ↗1“Oral poliomyelitis vaccine (OPV)” NCT00348881 ↗ |
| Modality | Vaccine | “Oral poliomyelitis vaccine (OPV)” NCT00348881 ↗ |
| Route | Oral | “Oral co-administered with study vaccine.” NCT00348881 ↗ |